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Summary The intensity of angiogenesis as measured by the density of microvessels has been reported to be associated with a poor
prognosis in invasive breast cancer in some, but not all, studies. The reasons for these discrepancies may be variations in the methodologies
used. The monoclonal antibody used to identify the microvessels, the number of high-density areas or 'hotspots' counted and the type of
value taken for statistical analysis (highest count or mean count) have varied between the different studies. We have assessed which of the
three commonly used monoclonal antibodies provides the best visualization of microvessels in invasive breast cancer and have used
methods that give reproducible data for the optimum number of 'hotspots' to count for each reagent. Thus, microvessels in formalin-fixed
paraffin-embedded specimens from 174 primary breast cancers were immunohistochemically stained with monoclonal antibodies to
FVIIIRAg, CD31 and CD34 and ten fields counted at 200 x magnification for each antibody. The highest count and the mean value of the
highest of three, five and ten counts were used to examine the relationship between the density of microvessels and overall survival of
patients with a median follow-up time of 7.1 years. Antibodies to CD31 and CD34 identified more vessels than antibodies to FVIIIRAg (median
highest count permm2: CD31 = 100, CD34 = 100, FVIIIRAg = 81). The monoclonal antibody to CD31, however, was the least reliable
antibody, immunohistochemically staining only 87% of sections compared with 98% for the monoclonal to CD34 and 99% for the monoclonal
to FVIIIRAg. There was a high degree of correlation between the number of vessels stained by the different antibodies, though there were
some considerable differences in actual counts for serial sections of the same specimen stained by the different antibodies. Patients could be
divided into two groups corresponding to those with high microvessel densities and those with low microvessel densities. Using Kaplan-Meier
survival curves, there was a close association for all three antibodies between vessel density and survival whichever method of recording the
highest vessel densities was used. Using log-rank tests and Cox's regression analysis, anti-CD34 gave the most significant results of the
three antibodies, whereas a simple cut-off at the 75th percentile for the high and low groups produced the best association with patient
survival. For anti-CD34 the highest microvessel density (P = 0.0014) and the mean value of the highest three microvessel densities
(P= 0.004) showed a good correlation with patient death, whereas for anti-CD31 (P= 0.008) and anti-FVIIIRAg (P= 0.007) the highest count
gave the best correlation using Cox's regression analysis.
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The role of angiogenesis in the growth of solid tumours is well
recognized (Folkman, 1990). Recently it has been suggested that
the intensity of angiogenesis, as measured by the intratumoral
microvessel density, may be inversely correlated with time of
survival ofpatients with invasive breast cancer (Bosari et al, 1992;
Horak et al, 1992; Weidner et al, 1992; Toi et al, 1993; Gasparini et
al, 1994; Obermair et al, 1994; Bevilacqua et al, 1995, Fox et al,
1995; Ogawa et al, 1995;), although not all studies have found this
association (Hall et al, 1992; Van Hoefet al, 1993; Axelsson et al,
1995; Goulding et al, 1995; Costello et al, 1995). This may be the
result of the different methodologies used both to stain and to
count the microvessels in the tumour.
Currently, monoclonal antibodies to endothelial cell antigens
are used to visualize the tumour blood vessels. Three antibodies
are frequently used: anti-FVIIIRAg (Burgdorf et al, 1981), anti-
CD31 (antibody JC70) (Parums et al, 1990) and anti-CD34 (anti-
body QBEND/10) (Ramani et al, 1990). FVIIIRAg or von
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Willebrand's factor is involved in platelet adhesion and aggrega-
tion (Fajardo, 1989); CD31 is associated with platelet adhesion in
inflammation and wound healing (Newman et al, 1990); and CD34
is believed to be involved in leucocyte adhesion and endothelial
cell migration during angiogenesis (Fina et al, 1990). Antibodies
to all three of these antigens have been used in research on the
association between the intensity of angiogenesis and clinical
outcome in breast cancer and other tumours (Srivastava et al,
1988; Horak et al, 1992; Macchiarini et al, 1992; Gasparini et al,
1993), although they have different sensitivities and immuno-
staining characteristics. The identity of the monoclonal antibody
used may therefore influence the results for a tumour's
microvessel density, although no study has compared these three
markers in a large series.
In addition to the differences between antibodies used to stain
histological sections, the method used to count vessels has also
varied considerably. Most studies have first scanned the relevant
histological sections at low magnification, x40 and x 100, to locate
the areas of greatest microvessel density (the so-called 'hotspots')
which tend to be found at the margins of the tumour (the so called
'leading edge'), and then counted individual microvessels, as
delineated by the stained endothelial cells, at x 200 magnification
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Table 1 Patient characteristics and Cox's regression analysis on patient
survival for conventional prognostic indicators.
Cox regression
Variable n r-value Chi-square P-value
Premenopausal 51
Post-menopausal 122 0.03 2.4 0.12
Age (years) 173 0.00 1.2 0.27
Grade
1 50
2 76 0.06 5.9 0.05
3 47 (2df)
Size (mm)
1-19 63
20 + 74 0.11 6.5 0.01
Node
-ve 84
+ve 36 0.17 8.7 0.003
Cox's regression analysis constructed for patients were total = n and
P= probability
(Weidner et al, 1991, 1992; Bosari et al, 1992; Horak et al, 1992;
Toi et al, 1993; Van Hoef et al, 1993; Gasparini et al, 1994;
Obermair et al, 1994; Axelsson et al, 1995). Early studies only
assessed one x 200 microscopic field for microvessel density and
this figure was used for statistical analysis. In subsequent studies,
the number of 'hotspots' counted for each tumour section has
varied from 1 to 5 and the density ofmicrovessels perfieldhas been
recorded either as the highest count (Weidner et al, 1991; Horak et
al, 1992; Gasparini et al, 1994) or as the mean ofthree, four or five
fields (Bosari et al, 1992; Hall et al, 1992; Toi et al, 1993; Van Hoef
et al, 1993; Miliaras et al, 1995; Ogawa et al, 1995). Only the
maximum number of microvessels is recorded because the intra-
tumoral vessel density is heterogeneous and it is thought that blood
vessel invasion and hence systemic dissemination oftumourcells is
more likely to occur in the areas ofhighest vessel density (Horak et
al, 1992). However, whetherthis is in fact true or not is unclear, and
certainly tumour emboli in vascular spaces have been reported at
sites other than the so-called 'hotspots' (Bettelheim et al, 1984; Lee
et al, 1986). Thus, although measuring the tumour microvessel
density appears to hold some promise as a potential prognostic
factor in patients with breast cancer, the methods used to assess it
require validation and standardization.
The aim of this study is to validate the methodology: firstly, by
comparing the monoclonal antibodies commonly used in diagnostic
practice to immunostain vascular endothelium in the same set of
archival breast carcinomas; and, secondly, by comparing the
methods used, to assess microvesseldensity withregard to 'hotspot'
identification and the ultimate value taken for statistical analysis.
MATERIALS AND METHODS
Patients and tumours
The study was based on a set of 174 patients who had sequentially
presented with primary symptomatic breast cancer to the Royal
Liverpool University Hospital between 1984 and 1991. Patients
included in the study had to have primary, unilateral breast cancer
that had been treated by wide local excision and radiotherapy or
modified radical mastectomy and had to have no other primary
cancer or disseminated disease at the time of diagnosis. Table 1
shows the clinicopathological characteristics of the patients.
Premenopausal node positive patients received adjuvant
chemotherapy and post-menopausal patients received tamoxifen
20 mg once a day. Patient follow-up was determined from the case
notes, GP records and the Mersey Cancer Registry and follow-up
was available in 173 patients (minimum 96 months). The time of
overall survival of each patient was calculated from the date of
first diagnosis to the date of death from whatever cause or to their
last outpatient appointment.
Table 2 Descriptive statistics for all counting methods
Microvessel density/mm-2
Antibody and 25th 75th Validh
fields counteda Mean ± s.d.b Minc centiled Mediane centile' Maxg n
Anti-CD34
High 121 60 37 78 100 157 418 171
x 3 107 54 35 69 90 138 393 171
x 5 100 51 32 65 85 126 368 170
x 10 87 46 28 54 74 107 301 170
Anti-CD31
High 113 51 35 76 100 140 278 151
x 3 103 47 32 69 93 129 271 151
* 5 96 44 29 63 85 118 263 151
x 10 84 41 26 53 74 101 234 150
Anti-FVIII
High 96 49 31 65 81 124 356 173
x 3 88 43 29 59 75 109 321 173
x 5 82 41 26 56 71 104 303 173
x 10 72 37 22 49 62 91 276 172
aMicrovessel densities were counted over the ten apparent highest fields, and the highest density (high), the mean values of the three highest densities (x 3),
the mean values of the five highest densities (x 5) and the mean values of all ten fields (x 10) were recorded for each antibody anti-CD34, anti-CD31 and anti-
FVIIIRAg; bmean ± standard deviation (s.d.) per mm2; cminimum (min) value of the highest microvessel densities per mm2; d25th percentile value; emedian value;
'75th percentile value; gmaximum (max) value of the highest microvessel densities per mm2; hnumber of stained tumours.
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Figure 1 Differences in the highest microvessel densities counted between
the antibodies. Box and whisker plot displaying median and interquartile
range (shaded area) and largest and smallest values that are not outliers
(whiskers). The box plot also includes two categories of cases with outlying
values. Those values more than three box-lengths from the upper or lower
edge of the box are called extreme values and are denoted by *.Cases with
values that are between 1.5 and 3 box lengths from the upper and lower
edge of the box are called outliers and are designated with a 0.
CD34V31 =CD34vsCD31 etc.
Selection of histological sections
The original haematoxylin and eosin (H & E) sections for the
primary tumours were reviewed and a block was selected that was
thought to be representative ofthe invasive component and which
included the leading edge of the tumour.
Immunocytochemistry
The monoclonal antibodies to the endothelial cells anti-CD31,
JC70A (Dako, Bucks, UK), anti-CD34, Q BEND/10 (Serotec,
Oxford, UK) and the polyclonal anti-human von Willebrand factor
(Dako) were purchased from their commercial suppliers. Each
selectedparaffin block was serially sectioned at4gim and dewaxed.
A trypsin digestion with 0.1I% trypsin and 0.1I% calcium chloride in
Tris-HCI pH 7.6 at 370C was required to expose the surface anti-
gens on the tissue sections (Curran et al, 1977). The digestion time
for the monoclonal antibodies was 30 min, whereas for the poly-
clonal antibodies it was 15 min Endogenous peroxidase in the histo-
logical sections was removed by prior incubation with 0.05% (w/v)
hydrogen peroxide in methanol. Immunocytochemistry was under-
taken using th'e avidin-biotin-peroxidase (ABC) method (Hsu et al,
1981). The primary monoclonal antibodies were diluted 1:5 for the
anti-CD31 and 1:100 for the anti-CD34 in phosphate-buffered
saline/0.5% bovine serum albumin (BSA) (w/v). These were added
to the dewaxed sections and incubated overnight at room tempera-
ture. A 1:200 dilution ofthe anti-human von Willebrand factor was
incubated for 2 h at room temperature. The optimum concentration
for each antibody was determined by assessing the microvessel
staining after incubation of a control tumour specimen with a serial
dilution of the primary antibody over various time periods.
Secondary antibodies were incubated for 1 h using biotinylated
donkey anti-rabbit (Amersham Intemnational, Bucks, UK) for the
polyclonal and biotinylated sheep anti-mouse (Amersham) for the
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Figure 2 Scatter plots of the highest counts for all three antibodies. Scatter
plots comparing the highest count for the three antibodies showing a high
degree of correlation. Spearman correlation coefficients between anti-CD31
vs anti-CD34 =0.79, anti-CD34 and FVIIIRAg = 0.87, and anti-CD31 and
anti-FVIIIRAg =0.81
monoclonal diluted to 1:200 in PBS/0.5% BSA (w/v). The bound
antibodies were detected using the avidin-biotin complex/horse-
radish peroxidase (HRP) (Dako) according to the manufacturer's
instructions and finally visualized using 0.05% 3 3' diaminobenzi-
dine in Tris-HCIpH 7.6plus 33 gl of30 volumehydrogenperoxide
per 100 ml. The cellular nuclei were counterstained blue with
Mayer's haemalum. Coverslips were mounted with DPX (Merk,
Poole, UK). Histological sections of the different tumours were
stained in batches of 20 for each-antibody with both a positive and
no-first-antibody negative control in each batch. If neither control
was satisfactory, the entire batch was restained.
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Table 3 Cox's regression analysis of patient survival for groups of 'low' and
'high' microvessel densities using the median as the cut-off value
Variablea Cox regressionb
r-Value Chi-square P-value
Anti-CD34
High 0.07 4.2 0.04
x 3 0.08 4.7 0.03
x 5 0.07 4.6 0.03
x10 0.00 1.9 0.17
Anti-CD31
High 0.00 1.5 0.23
x 3 0.05 3.2 0.08
x 5 0.05 3.2 0.07
x 10 0.05 3.1 0.08
Anti-FVIII
High 0.04 2.9 0.09
x 3 0.01 2.1 0.15
x 5 0.00 2.0 0.16
x10 0.03 2.4 0.12
aMicrovessel densities were counted over the ten apparent highest fields, and
the highest density (high), the values of the three highest densities (x 3), the
values of the five highest densities (x 5) and the values of all ten fields (x 10)
were recorded for each antibody anti-CD34, anti-CD31 and anti-FVIIIRAg;
bCox's regression analysis constructed for patients (total = n) with
microvessel densities above (high) and below (low) the median;
P = probability.
Assessment of microvessel density
The microvessel densities of stained sections from the chosen
paraffin blocks were assessed blind, without any knowledge ofthe
patients' previous investigations or outcome, based on a modifica-
tion of the method described by Weidner et al (1991). The areas
containing the greatest numbers of microvessels or 'tumour hot
spots' were identified by scanning the stained sections at low
magnification (x 40 and x 100) using a light microscope. Once
these areas were recognized, individual stained microvessels were
point-counted at x 200 magnification using a square grid graticule.
This corresponded to a field size of 0.68 mm2 (all figures in text
are quoted per mm2). Ten fields per tumour section were counted
in the areas that appeared to contain the greatest number of
microvessels on scanning at low magnification. The first count
performed was the field thought to contain the highest number of
microvessels found at low magnification, and each subsequent
count was the field thought to be the next highest. Large micro-
vessels as well as any single brown-staining endothelial cell,
clearly separate from other microvessels, were included in the
microvessel count; branching structures were counted as one,
unless there was a break in the continuity of the vessel, in which
case it was counted as two distinct vessels. From the ten fields
counted for each of the antibodies, the highest number of
microvessels per field and the means ofthe highest three, five and
ten fields were then used for subsequent analysis.
Statistical analyses
Survival curves of numbers of patients were plotted against time
using the Kaplan-Meier method and the differences between the
curves for the different groups of patients were assessed by the
log-rank test. The patients were divided into two groups: those
Table 4 Cox's regression analysis on patient survival using microvessel
densities as a continuous variable
Variablea Cox regressionb
n r-value Chi-square P-value
Anti-CD34
High 170 0.16 10.7 0.001
x 3 170 0.15 9.0 0.003
x 5 169 0.13 7.6 0.006
x10 169 0.14 8.0 0.005
Anti-CD3
High 150 0.12 7.1 0.008
x 3 150 0.12 6.9 0.009
x5 150 0.12 6.3 0.012
x 10 149 0.11 6.0 0.014
Anti-FVIII
High 172 0.12 6.8 0.009
x 3 172 0.13 7.3 0.007
x 5 172 0.13 7.2 0.007
x 10 171 0.12 6.2 0.013
aMicrovessel densities were counted over the ten apparent highest fields, and
the highest density (high), the values of the three highest densities (x 3), the
values of the five highest densities (x 5) and the values of all ten fields (x 10)
were recorded for each antibody anti-CD34, anti-CD31 and anti-FVIIIRAg;
bCox's regression analysis constructed for patients (total = n) with
microvessel densities assessed as a continuous variable; P= probability.
Table 5 Cox's Regression analysis on patient survival for groups of 'low'
and 'high' microvessel densities using the 67th, 75th, 80th and 90th
percentile cut-off values for the highest microvessel densities
Variablea Cox regressionb
n r-Value Chi-square P-value
Anti-CD34
67th 170 0.16 13.5 0.0002
75th 170 0.14 10.2 0.0014
80th 170 0.17 13.0 0.0003
90th 170 0.16 10.2 0.0014
Anti-CD31
67th 150 0.09 5.4 0.0204
75th 150 0.12 7.0 0.0081
80th 150 0.09 4.5 0.0346
90th 150 0.12 6.0 0.0141
Anti-FVIII
67th 172 0.08 4.6 0.0317
75th 172 0.12 7.3 0.0048
80th 172 0.14 8.9 0.0029
90th 172 0.07 3.5 0.0616
aMicrovessel desities were counted over the ten apparent highest fields for
each section, and the highest value recorded for each antibody (anti-CD34,
anti-CD31 and anti-FVIIIRAg) and divided into 'low' and 'high' groups using
the 67th, 75th, 80th and 90th centiles as cut-off points. bCox's regression
analysis constructed for patients (total = n) with microvessel densities
assessed as a categorical variable using various cut-off values;
P= probability.
with tumours with a high microvessel density and those with
tumours with a low microvessel density. The cut-off values
between these two groups of patients were examined using the
median or 50th centile and the 67th, 75th, 80th and 90th centiles of
the total microvessel densities.
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A Cox's proportional hazards regression model was also used
to compare these high- and low-count survival curves for the
different antibodies and counting methods used, as well as evalu-
ating the conventional prognostic indicators. Prognostic signifi-
cance was assessed using the likelihood ratio chi-square test and
by the r statistic. The higher the r statistic in these analyses the
greater the association with survival.
All analyses were undertaken using the SPSS V6.1 package for
windows.
RESULTS
Of the initial 174 patients, complete follow-up was available on
173, who were used for the survival analysis (one patient
emigrated soon after her surgery). The median follow-up time was
7.1 years. The mean age at diagnosis was 55 years, with a standard
deviation of 12 years.
Comparison of immunocytochemical staining
Of the three antibodies used, the antibody to CD34 was the most
strongly expressed on microvessels at the optimum concentration
used. At the optimum concentration, this antibody did not stain any
tumour or inflammatory cells, there was little background staining,
and hence it was found to be the easiest to use for counting
microvessels. The monoclonal antibody to FVIIIRAg also showed
strong staining of the microvessels, however, this antibody at the
optimum concentration for staining the microvessels also stained
some tumour and inflammatory cells, as well as some connective
tissue, thus making the counting of microvessels more difficult. In
contrast, staining of the microvessels with monoclonal antibodies
to CD31 was not as strong as for the other two antibodies, even
although the highest concentrations were used and despite ampli-
fied staining techniques. The antibody to CD31 also stained inflam-
matory cells. Consequently, these facts made identifying the areas
of greatest microvessel density more difficult at low magnification
and counting the microvesels at high magnification was also diffi-
cult. Of the three antibodies used, that to FVIIIRAg was the most
reproducible with 99% of histological sections stained on the first
run. Antibodies to CD34 stained 98% and antibodies to CD31
stained only 87% ofsections on the first run despite amplification.
The antibodies differed in their microvessel staining specifici-
ties. Both antibodies to CD34 and CD31 stained single isolated
endothelial cells as well as large microvessels, whereas antibodies
to FVIIIRAg mainly stained the larger microvessels. This resulted
in anti-CD34 and anti-CD31 highlighting more vessels than anti-
FVIIIRAg, and anti-CD34 reproducibly staining more microves-
sels than anti-CD31 (Table 2). The differences between the highest
microvessel counts are summarized in Figure 1. The highest anti-
CD34 microvessel count exceeded the corresponding anti-CD31
count in 54% of tumours, the median difference was 4 (P = 0.01
Wilcoxon matched-pairs test). Anti-CD34 microvessel count
exceeded anti-FVIIIRAg count in 88% of tumours, the median
difference was 19 (P < 0.0001 Wilcoxon matched-pairs test) and
anti-CD31 count exceeded anti-FVIIIRAg in 79% of tumours,
the median difference was 15 (P< 0.0001 Wilcoxon matched-pairs
test). Half of all differences between microvessel counts for the
different antibodies were within 20 of the median, and 95% of all
differences were within 80 ofthe median (Figure 1).
Scatter plots comparing the highest counts for all three anti-
bodies are shown in Figure 2 and suggest that a high degree of
correlation exists between the antibodies. All three counts display
a slight positive skewness and Spearman correlation coefficients
between anti-CD34 and anti-CD31 = 0.79, between anti-CD34 and
anti-FVIIIRAg = 0.87, between anti-CD31 and anti-FVIIIRAg =
0.81. Similar patterns emerged between antibodies for all the other
methods of recording microvessel densities whether the means of
three, five or ten highest microvessel densities were recorded,
similar discrepancy summaries, scatter plots and Spearman corre-
lations were found. Median differences from the highest count to
the averages of three, five and ten fields were: anti-CD34 = 9, 15,
26; anti-CD31 = 7, 13, 26; anti-FVIIIRAg = 6, 12, 21 per mm2.
Assessment of highest microvessel density
Each section was scanned by eye at low magnification (x 40 and
x 100) to identify the areas of greatest microvessel density or
'hotspots' as described in Materials and methods, and the ten
'hottest spots' counted for each tumour section. However,
although the first field counted at high power was that thought to
contain the greatest number ofmicrovessels, this actually occurred
in only 20% of sections for all three antibodies. Moreover, when
the microvessels in the apparent highest five fields found by eye
were counted, the actual highest microvessel count had still only
been found in 65% ofthe sections and this value was again consis-
tent for each ofthe three antibodies.
Association of microvessel density and patient survival
Of the 173 patients with known follow-up, 59 had died (34%), 45
ofthese deaths (26%) were secondary to metastatic cancer, leaving
14 patients (8%) who died from other causes. The median highest
microvessel densities for those patients dying from metastatic
cancer were: anti-CD34 = 144; anti-CD31 = 124 and anti-
FVIIIRAg = 99 microvessels permm2. For other patients the
median highest counts were: anti-CD34 = 96; anti-CD31 = 97 and
anti-FVIIIRAg = 78 microvessels per mm2.
To examine the association between the microvessel density and
patient survival, the patients were divided into two groups, low and
high, initially on the basis of the median of the microvessel densi-
ties, thus converting a continuous variable into a categorical
variable. Kaplan-Meier survival curves for patients in the two
groups were compared using the log-rank test. Using this method of
analysis, only anti-CD34 was associated with significant differ-
ences in survival and that was only for the highest microvessel
count andthe mean ofthehighestthree andfivefields. Although the
other antibodies showed similar tendencies these were not statisti-
cally significant. Groupings ofpatients intolow and high by median
value ofthe microvessel densities were also entered separately into
aCox's proportional hazards regression model. Resulting likelihood
ratio and chi-squared tests of whether the groupings contributed
significant information gave almost identical P-values to those
from the log-rank test (Table 3). Patients with lower counts were
surviving longer than patients with higher counts.
When the microvessel densities of all patients were analysed
using a Cox's regression model as a continuous rather than a cate-
gorical variable all three antibodies and each of the four counts,
i.e. the highest and the mean of the highest three, five and ten
counts, showed a significant association with patient survival
(Table 4). When all the counts for each of the antibodies were
entered into a stepwise regression model, the highest anti-CD34
microvessel density showed the closest association with patient
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Table 6 Cox's regression analysis of patient survival for groups of 'low' and
'high' microvessel densities using the 75th percentile as the cut-off value
Variablea Cox regressionb
n r-Value Chi-square P-value
Anti-CD34
High 170 0.14 10.2 0.0014
x 3 170 0.16 12.7 0.0004
x 5 169 0.14 9.6 0.0019
x 10 169 0.13 8.0 0.0046
Anti-CD31
High 150 0.12 7.0 0.0081
x 3 150 0.10 5.6 0.0179
x 5 150 0.08 4.3 0.0392
x 10 149 0.07 3.6 0.0568
Anti-FVIII
High 172 0.12 7.3 0.0068
x 3 172 0.12 7.1 0.0075
x 5 172 0.12 7.1 0.0075
x 10 172 0.09 4.8 0.0277
aMicrovessel densities were counted over the ten apparent highest fields,
and the highest density (high), the values of the three highest densities (x 3),
the values of the five highest densities (x 5) and the values of all ten fields
(x 10) were recorded for each antibody anti-CD34, anti-CD31 and anti-
FVIIIRAg; bCox's regression analysis constructed for patients (total = n) with
microvessel densities assessed as a categorical variable using the 75th
percentile as a cut-off value; P = probability.
survival (%2 = 10.7, 1 d.f., P = 0.001, r = 0.16, n = 148). No other
antibody count could be added to this model at the 5% level of
significance. If the log of the microvessel densities was analysed
instead, thereby reducing undue influence of extreme counts on
the results, virtually identical results were obtained.
We also tested the effect of dividing the patients into high and
low groups using a cut-off for microvessel density at the 67th,
75th, 80th and 90th percentiles using Cox's regression analysis
(Table 5). This method of subdividing patients produced signifi-
cant results for all antibodies. Using the r statistic as the guide, a
good predictive model was achieved for each antibody by
grouping the patients into low and high microvessel densities
using a cut-off at the 75th percentile (Tables 5 and 6). Again the
number of fields counted resulted in different degrees of signifi-
cance. In this case the average of the three highest anti-CD34
microvessel densities gave the best predictive model (%2 = 12.7, 1
d.f.,P=0.0004, r=0.16,n= 170).
The75thpercentile values forthecut-offs aregiveninTable2, and
survival curves forpatients grouped intohighandlow in this way, for
the highest count ofall three antibodies are shown in Figure 3.
Multivariate analyses
Patient age, menopausal status, tumourgrade, size and nodal status
were examined as conventional prognostic factors (Table 1).
Kaplan-Meier and Cox regression methods produced almost iden-
tical P-value results. Nodal status was the main predictor ofpatient
survival and its r statistic was ofsimilar magnitude to that reported
for the anti-CD34 antibody.
Median and interquartile ranges for the highest anti-CD34
counts were 96 (71,126) for node negative cases and 112 (85,187)
for node positive cases (Mann-Whitney test P = 0.02). The 75th
percentile cut-offforhighestanti-CD34 counts was 107. In 20% of
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Figure 3 Patient survival curves grouped according to 'high' and 'low'
(<75%) microvessel densities for all three antibodies. Patients were split into
two groups depending on their tumour microvessel densities. Tumours with a
'high' vessel density (> 157 for anti-CD34, > 140 for anti-CD31 and > 124 for
anti-FVIIIRAg per mm2, split by the 75th percentile) or 'low' (< 157 for anti-
CD34, < 140 for anti-CD31 and < 124 foranti-FVIIIRAg per mm2) and the
time to death from diagnosis were recorded for each patient
node negative and in 31% ofnode-positive cases counts were 107
or above(2= 1.3, 1 d.f., P= 0.25).
When age, menopausal status, tumour grade, size and nodal
status were entered into a Cox stepwise regression model, only
British Journal ofCancer(1997) 76(8), 1046-1054
U.UA m..- m., - - - - - 1- -I
%..
0 CancerResearch Campaign 19971052 L Martin etal
Node positive interpreted as a predictor of metastatic spread in breast cancer.
1.0 < Since then the repeated studies have been conflicting, some
reporting a significant association with survival others not
0I9 _ observing any differences. A potential explanation for this vari- 0.8a, , ability is a lack ofconsistency in methodology. In order to address
0.74l ithis problem we have compared the staining properties ofthe three
0.64 | ,common monoclonal antibodies used to highlight microvessels
0.5, |and validated the counting technique for angiogenic assessment.
0.46 9We found anti-CD34 to be the most sensitive antibody for identi-
0.34 |fying endothelial cells, although anti:CD31 was nearly as sensi-
0.2, tive. Both Horak et al (1992) and Toi et al (1993) also found
anti-CD31 tobe more sensitive than anti-FVIIIRAg foridentifying
endothelial cells, although Siitonen et al (1995) found anti-
0 500 1000 1500 2000 2500 3000 FVIIIRAg to be the most sensitive. In apparent contrast to our
Survival in days results Horak et al(1992) found that anti-CD31 was more sensitive
than anti-CD34 at identifying endothelial cells, although no details
were reported ofhow many sections were compared. In our study
Node negative anti-CD31 was not such a robust marker as anti-CD34 and
1.0 - repeated stainings were necessary to obtain reproducible results.
Although staining revealed differences in numbers of micro-
o 8- \ , ,vessels, thecorrelation coefficients between those stainedby anti-
CD34 and anti-FVIIIRAg were better than when comparison was
0.7- made between those stained by anti-CD31 and anti-CD34 and
0.6- between anti-CD31 and anti-FVIIIRAg. This reflected the fact
0.5, that, both in our study and in other studies (Siitonen et al, 1995),
anti-CD31 was a rather unreliable antibody with weak endothelial
cell-staining properties. When the concentration of this antibody
0.3- was increased to intensify the staining of the endothelial cells, we
0.2- found that staining of inflammatory cells and connective tissue
0.11 also increased to such an extent that iteffectively masked staining
ofthe endothelial cells.
0 500 1000 150o o2000 2500 3000 We deviated from the method of counting microvessels as
Survival in days described by Weidner et al (1991) by counting the apparent ten
highestfields athighpower as foundby eye. Thiscounting method Figure 4 Survival curves for node positive and node negative patients his fied at hgpowr ascfoundtbye is cogemeod grouped according to 'high' and 'low' microvessel densities for anti-CD34. has confirmed that tumour microvasculature is heterogeneous and
Patients were stratified according to nodal status and then split into two it is the highest microvessel density per high-power microscopic
groups depending on their tumour microvessel densities. Tumours with a field that is best associated with patient death. The ability to locate
'high' vessel density (> 157 vessels mm-2, split by the 75th percentile) or 'low'
(< 157 vessels mm-2) and the time to death from diagnosis were recorded for the high-power microscopic field that contains the highest
'each patient microvessel density would therefore appear to be important in
obtaining a correlation with poor patient survival. From a biolog-
ical point ofview it would seem that tumour dissemination is more
nodal status emerged as a significant predictor of survival (X2 = likely to occur at sites of high vessel density and this would seem
9.0, 2 d.f., P = 0.011, n = 170). However, the highest anti-CD34 to be in accordance with our findings. This difficulty in recog-
count did add significantly to nodal status as a predictor ofsurvival nizing the vascular 'hotspots' may account for those studies that
(additional X2 = 11.9, 1 d.f., P = 0.0006), as did a 75th percentile failed to find an association between microvascular density and
cut-offforthe highest count (additional x2 = 10.4, 1 d.f., P = 0.0013) poor patient survival (Hall et al, 1992; Van Hoef et al, 1993;
and a 75th percentile cut-off for the average of the highest three Axelsson et al, 1995; Costello et al, 1995; Goulding et al, 1995;
counts (additional X2 = 11.5, 1 d.f., P = 0.0007) in separate analyses. Miliaras et al, 1995) and may limit the value of this technique in
The median cut-off did not add significantly to nodal status (addi- clinical practice. A more objective method of assessment is there-
tional X2 = 3.5, 1 d.f., P = 0.06). A 75th percentile cut-off for fore needed. In this study, we assessed the microvessel density in a
neither highest anti-CD31, nor highest anti-FVIIIRAg, added manner similar to assessing the mitotic rate in breast cancer
significantly to the predictive model comprising nodal status and grading, a method familiar to all pathologists. When grading a
anti-CD34. Kaplan-Meier survival curves for the 75th percentile breast cancer, the mitotic rate is assessed by counting the number
cut-offs for the highest anti-CD34 count by nodal status are shown of mitoses in ten high-power fields and using the highest count
in Figure 4. found. This method is very similar to that described by Weidner et
al (1991) in vascular 'hotspot' selection, although he recommends
DISCUSSION scanning the tumours to identify the 'hottest spot' and counting
one field only. We scanned the tumours at low magnification to
Weidner et al (1992) first reported that high densities of immuno- identify the ten 'hottest spots' and, once found, point-counted
histochemically stained microvessels in the primary tumour were labelled vessels at 200 x magnification. Although counting ten
associated with early demise of the patient and hence could be fields for each tumour is a very laborious technique, we found that
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the apparent 'hottest spot' for microvasculature estimated by eye
at low magnification after scanning often did not contain the
highest piicrovessel density at high magnification. For all three
antibodies, the first count in fact was only the highest in 20% of
cases, and after counting the apparent highest five fields, the
highest count had still only been found in 65% of cases. This
confirms the difficulty in recognizing the most vascular area ofthe
tumour that appears critical to assess accurately the association
between tumour progression and the angiogenic potential.
Counting ten fields greatly reduces the chance ofmissing the most
vascular area, and we feel this will shorten the training period
needed to perform vascular counts consistently, making the
methodology more practical in routine clinical practice. Once the
'hotspots' have been identified the use of a Chalkey graticule
(Chalkey et al, 1943; Fox et al, 1995) or computerized image
analysis system (Barbareschi etal, 1995) to countthe microvessels
may further reduce subjectivity.
In this study, we have examined the association between the
highest microvessel density and early death ofpatients for each of
the antibodies using a univariate analysis (Tables 3, 4 and 5).
Firstly, the median value of microvessel densities was used as our
cut-off to divide the patients into two groups of tumours of high-
and low-microvessel densities. This procedure enabled a contin-
uous variable to be converted into categorical values, and hence an
inverse association of microvessel density and patient survival
could be attempted. The use of the median value of microvessel
densities as the cut-offbetween the two patient groups is in agree-
ment with the cut-off value used in the majority of studies
(Weidner et al, 1991; Bosari et al, 1992; Horak et al, 1992; Toi et
al, 1993; Fox et al; 1994 Axelsson et al, 1995). Using the median
as a cut-off, only anti-CD34 gave a significant inverse association
ofmicrovessel density andpatient survival. However, ifthe cut-off
between the tumours in the two groups ofpatients was increased to
the 75th percentile, all the antibodies gave a significant inverse
association between these parameters. However, it should be noted
the strongest association between survival and the microvessel
density was found when examined as a continuous variable. In a
recent international consensus paper, Vermeulen et al (1996) argue
that categorizing tumours into 'high' and 'low' microvessel
groups discards information, and that a multiparametric formula
should be devised in which the microvessel density is entered
together with other established prognostic factors, to yield an
individual risk factor on a continuous scale. Our data suggest that
using the microvessel density in this way would give the greatest
prognostic information. Until this time, if angiogenic assessment
is to be used in the future for any form ofprognosis and to assess
those tumours which may be suitable for any anti-vascular drug
treatments, a cut-off value must be universally agreed.
When we analysed patient survival for the conventional prog-
nostic markers in this series nodal status was the main predictor of
survival. Although there was an association between nodal status
and the microvessel density, the microvessel count did act as an
independent predictor for both node-negative and -positive
patients. It should, however, be emphasized that our results are
based on descriptive statistics and hence the prognostic ability is
reported as optimized forthis particular setofpatients. Prospective
validation ofthis technique now needs to be considered.
In summary, this study has validated the role of angiogenesis in
breast cancer, in which the highest microvessel density is associ-
ated with poorer patient prognosis, and hence suggests that it is an
important step in dissemination of breast cancer, independent of
lymph node status. As finding the highest microvessel density is
critical in assessing a tumour's angiogenic potential, and appears
to be the most subjective step in the methodology, we advocate the
counting of the ten highest fields. Moreover, of the three anti-
bodies commonly used to stain endothelial cells, anti-CD34 is the
most sensitive and reliable antibody, providing the highest associ-
ation in this study and therefore may be the most useful for
obtaining prognostic information in the future.
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